Valuation: Lundbeck

Market Cap 44.14B 6.65B 5.9B 5.53B 5.01B 9.46B 641B 9.53B 66.37B 25.81B 327B 24.97B 24.43B 1,052B P/E 2026 *
9.93x
P/E 2027 * 9.69x
Enterprise Value 48.14B 7.25B 6.44B 6.03B 5.46B 10.32B 699B 10.39B 72.38B 28.15B 357B 27.23B 26.65B 1,147B EV / Sales 2026 *
1.86x
EV / Sales 2027 * 1.68x
Free-Float
30.74%
Yield 2026 *
3.46%
Yield 2027 * 3.12%
1 week+1.76%
Current month+1.23%
1 month-1.70%
3 months+17.48%
6 months+26.75%
Current year+19.67%
1 week 5.51
Extreme 5.51
5.82
1 month 5.24
Extreme 5.24
5.98
Current year 4.22
Extreme 4.22
5.98
1 year 4.22
Extreme 4.22
5.98
3 years 3.12
Extreme 3.125
5.98
5 years 3.03
Extreme 3.028
10.99
10 years 3.03
Extreme 3.028
10.99
Manager TitleAgeSince
Chief Executive Officer 59 30/09/2023
Director of Finance/CFO 49 31/08/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 24/03/2015
Director/Board Member 67 24/03/2015
Director/Board Member 60 19/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.76% - - 6.65B
+1.26%-2.29%+36.97%+104.79% 1,032B
+0.73%-4.78%+35.41%+61.62% 614B
+0.35%+1.29%+15.86%+79.90% 471B
+1.72%-4.92%+59.84%+36.64% 350B
+0.80%+1.03%+22.25%+40.60% 337B
+0.78%-1.62%+12.23%+33.92% 268B
-0.10%-2.87%-6.67%+9.87% 246B
-0.09%-4.97%+36.88%+50.52% 218B
-0.28%-4.66%+26.99%+92.98% 179B
Average +0.22%-3.39%+26.64%+56.76% 412.76B
Weighted average by Cap. -0.01%-3.18%+29.69%+67.10%

Financials

2026 *2027 *
Net sales 25.87B 3.9B 3.46B 3.24B 2.94B 5.54B 376B 5.58B 38.9B 15.13B 192B 14.64B 14.32B 616B 26.1B 3.93B 3.49B 3.27B 2.96B 5.59B 379B 5.63B 39.25B 15.27B 193B 14.77B 14.45B 622B
Net income 4.57B 688M 611M 572M 518M 979M 66.35B 986M 6.87B 2.67B 33.85B 2.58B 2.53B 109B 4.62B 696M 618M 578M 524M 990M 67.11B 997M 6.95B 2.7B 34.24B 2.61B 2.56B 110B
Net Debt 4B 603M 536M 501M 454M 858M 58.15B 864M 6.02B 2.34B 29.67B 2.26B 2.22B 95.37B -182M -27.4M -24.32M -22.76M -20.63M -38.96M -2.64B -39.24M -273M -106M -1.35B -103M -101M -4.33B
Projected Income Statement - Annual - Lundbeck
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
05/10/26 €5.780 +1.58% 0
05/10/26 €5.690 +2.15% 7
02/10/26 €5.570 +0.91% 8
01/10/26 €5.520 -3.33% 1,761
30/09/26 €5.710 +0.53% 52
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Lundbeck
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
44.86DKK
Average target price
49.19DKK
Spread / Average Target
+9.66%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lundbeck